Lunai Bioworks Inc.

1.4200+0.00 (+0%)

Sep 30, 4:00:00 PM EDT · NasdaqCM · RENB · USD

Upcoming Earnings

Report date

≈ Nov 13, 2025 (in 14 days)

Key Stats

Market Cap

33.82M

P/E (TTM)

Basic EPS (TTM)

-10.80

Dividend Yield

Recent Filings

10-K

FY2025 results

9/29/25Sep 29, 2025

Lunai Bioworks Inc. reported a net loss of $178.0 million for FY2025 ended June 30, 2025, up 101% y/y from $88.4 million, driven by a $170.4 million goodwill impairment on its AI diagnostics unit amid funding challenges, though offset by a $11.7 million gain from revaluing contingent consideration. No revenue was generated as a pre-clinical biotech and AI firm, with operating expenses rising 131% to $189.0 million, including the impairment, while G&A fell 27% to $17.9 million and R&D dropped 80% to $0.5 million from discontinued projects. Q4 saw sequential momentum in AI platform validation but deteriorated liquidity, ending with $0.1 million cash and $28.1 million working capital deficit; debt restructuring converted $9.7 million notes to 53.6 million shares post-year-end. Free cash flow was negative $8.4 million annually, with no dividends or buybacks; capex remained minimal. No FY2026 guidance disclosed. Ongoing litigation over past IP disputes risks further quarterly volatility.

8-K

Subsidiary bankruptcy impairs assets

9/5/25Sep 5, 2025

Lunai Bioworks' indirect subsidiary Gedi Cube B.V. filed for voluntary bankruptcy in the Court of Amsterdam on September 2, 2025, due to payment shortfalls, triggering a material asset impairment charge expected in Q3 results. Management is monitoring supply chain ripples and customer ties while rolling out contingency plans to curb disruptions. Lunai and other units keep running normally. No estimate yet on the impairment hit.

8-K

Name change to Lunai Bioworks

8/26/25Aug 26, 2025

Renovaro Inc. changed its name to Lunai Bioworks Inc., effective August 20, 2025, after filing the amendment on August 18. The Nasdaq ticker remains RENB, but the CUSIP updates accordingly. This rebrand signals a fresh start amid efforts to regain Nasdaq compliance. No business disruption expected.

8-K

Nasdaq compliance extension granted

8/6/25Aug 6, 2025

Renovaro Inc. faced Nasdaq delisting risk after missing its annual shareholder meeting deadline, but secured an extension to October 31, 2025, to hold it and regain compliance. The company plans to act within this window. Compliance hinges on timely execution.

8-K

Chairman resigns for new role

7/25/25Jul 25, 2025

Renovaro Inc. announced on July 25, 2025, that Maurice van Tilburg resigned as Chairman of the Board, effective August 22, 2025, to take a leadership role at an unrelated company, limiting his availability. No disagreements with the company's operations or policies prompted the move. The board expressed thanks for his service. Leadership transition underway.

About

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

CEO

Mr. David H. Weinstein

IPO

2/2/2015

Website

https://renovarogroup.com

Sector

Healthcare

Industry

Biotechnology